Immunologic Factor
lexatumumab
[ lek-suh-too-moo-mab ]
Definitions related to lexatumumab:
-
A fully human monoclonal agonistic antibody directed against tumor necrosis factor-alpha (TNF-alpha)-related apoptosis-inducing ligand receptor-2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural ligand TRAIL, lexatumumab binds to and activates TRAIL-R2, which may trigger apoptosis in and inhibit the growth of TRAIL-R2-expressing tumor cells. TRAIL-R2, also known as death receptor 5 (DR5), is a member of the TNF receptor family and is expressed on many malignant cell types.NCI ThesaurusU.S. National Cancer Institute, 2021
-
A substance being studied in the treatment of some types of cancer. It binds to a protein called TRAIL-R2 on the surface of some tumor cells, which may kill the tumor cells. HGS-ETR2 is a type of monoclonal antibody.NCI Dictionary of Cancer TermsU.S. National Cancer Institute, 2021
Return to OpenMD Medical Dictionary
> L
This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.